The aim of this study is to explore the economic and social impacts of digitalization in rural areas of Hungary, with particular attention to the role of infrastructural development, digital skills, opportunities for the younger generation, and the adaptability of rural enterprises. The research is based on secondary data analysis, drawing from national and international databases to examine the current state, challenges, and opportunities of rural digitalization. The findings reveal that, although infrastructural improvements—especially in broadband network coverage—have brought significant progress, the digital transition is still hindered by a lack of financial resources, insufficient digital competencies, and limited access to technological innovation. The study emphasizes that digitalization in rural areas is not merely a matter of technology but also a strategic tool for promoting social equity and territorial cohesion. Accordingly, the author proposes the implementation of complex, targeted, and community-oriented development policies to support inclusive rural digital transformation.
Protein tyrosine phosphatase non-receptor type 2 (PTPN2) is ubiquitously expressed, primarily in hematopoietic and placental cells. Critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens. Historically, phosphatases are difficult drug targets; due to an intrinsic physicochemical profile of phosphatase inhibitors, finding bioavailable molecules is a great challenge. ZE00-0388 demonstrates sub-nanomolar PTPN2/N1 inhibitory activity and outstanding over 1000-fold selectivity against all other phosphatases. ZE00-0388 demonstrated complete tumor remission in combination with the anti-mPD-1 recombinant mAb therapy in the murine colon adenocarcinoma MC38 in vivo model. ZE00-0388 demonstrates good safety and tolerability; its ADME properties confirm that ZE00-0388 is suitable for further development for combination therapies. Alexei Pushechnikov, Vladislav Parchinsky, Aleksei Riakhovskii, Stepan Mochalov, Ruben Karapetian, Amy Burd, Nikolay Savchuk, Iain Dukes, Ruben Abagyan. Discovery and preclinical evaluation of a potent, orally bioavailable, highly selective, small molecule PTPN2/1 inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5607.
